Search Results

Taysha Gene Therapies, Inc. announced that, on June 3, 2024, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase 360,000 shares of the Company’s common stock in connection with their employment.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Taysha Gene Therapies, Inc. announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

Taysha Gene Therapies, Inc. announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions.

Taysha Gene Therapies, Inc. announced that, on May 1, 2024, the Compensation Committee of Taysha’s Board of Directors granted four new employees, in the aggregate, options to purchase 528,000 shares of the Company’s common stock in connection with their employment.

Taysha Gene Therapies, Inc. today announced the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.